Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 24, 2025 • 9:01 PM ET

Date/Time Source News Release
04/07/2025 04:05 PM EDT GlobeNewswire Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
03/27/2025 05:44 PM EDT GlobeNewswire Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
03/19/2025 08:00 AM EDT GlobeNewswire Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
02/05/2025 08:00 AM EST GlobeNewswire Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
11/13/2024 07:00 AM EST GlobeNewswire Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
10/17/2024 08:00 AM EDT GlobeNewswire Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
10/16/2024 04:00 PM EDT GlobeNewswire Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11/2024 08:00 AM EDT GlobeNewswire Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Page
  • 1

Additional News

As of April 24, 2025 • 9:01 PM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.